New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
07:44 EDTONTX, BAXRigosertib failure removes positive catalyst for Baxter, says Leerink
Leerink says Onconova's (ONTX) announcement last night that pivotal results of IV rigosertib in myelodysplastic syndrome failed to meet its primary endpoint as removing a positive catalyst for Baxter (BAX) since Baxter has the European rights to rigosertib. Leerink points out that Baxter had previously noted that rigosertib could ultimately be a $1B drug. However, the firm believes rigosertib was largely not reflected in estimates for Baxter and it reiterates an Outperform rating on the stock.
News For BAX;ONTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
09:08 EDTBAXBaxter announces Illinois headquarters for biopharmaceutical spin-off
Subscribe for More Information
February 20, 2015
07:08 EDTBAXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTBAXPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use